Lead sponsor
Suven Life Sciences Limited
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
1
Ongoing
939
Total enrollment
114
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Phase 3
1
Not applicable
1
Trials by status
Recruiting
1
Completed
1
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a StudyAlzheimer's diseasePh 2Completed564
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Recruiting375